| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
|
N Engl J Med
|
2012
|
4.26
|
|
2
|
Incidence of and risk factors for nodding off at scientific sessions.
|
CMAJ
|
2004
|
2.97
|
|
3
|
Ibrutinib in previously treated Waldenström's macroglobulinemia.
|
N Engl J Med
|
2015
|
2.04
|
|
4
|
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
|
Blood
|
2013
|
1.79
|
|
5
|
Digoxin prescribing for heart failure in elderly residents of long-term care facilities.
|
Can J Cardiol
|
2005
|
1.46
|
|
6
|
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
|
Blood
|
2013
|
1.44
|
|
7
|
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
|
Blood
|
2013
|
1.38
|
|
8
|
Association between psychotropic drug use and heart failure therapy in elderly long-term care residents.
|
J Am Geriatr Soc
|
2006
|
1.38
|
|
9
|
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
|
J Clin Oncol
|
2009
|
1.38
|
|
10
|
Nodding and napping in medical lectures: an instructive systematic review.
|
CMAJ
|
2005
|
1.30
|
|
11
|
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.
|
Exp Hematol
|
2007
|
1.26
|
|
12
|
Heart failure and cognitive impairment: challenges and opportunities.
|
Clin Interv Aging
|
2007
|
1.18
|
|
13
|
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
|
J Clin Oncol
|
2008
|
1.15
|
|
14
|
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
|
Br J Haematol
|
2012
|
1.14
|
|
15
|
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
|
Blood
|
2008
|
1.09
|
|
16
|
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.
|
Clin Lymphoma Myeloma
|
2007
|
1.07
|
|
17
|
Thalidomide and rituximab in Waldenstrom macroglobulinemia.
|
Blood
|
2008
|
1.03
|
|
18
|
Management of heart failure in Canadian long-term care facilities.
|
Can J Cardiol
|
2004
|
1.02
|
|
19
|
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
|
Clin Cancer Res
|
2009
|
1.00
|
|
20
|
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
|
Clin Cancer Res
|
2008
|
0.97
|
|
21
|
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.
|
Haematologica
|
2009
|
0.94
|
|
22
|
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
|
Br J Haematol
|
2011
|
0.92
|
|
23
|
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
|
Br J Haematol
|
2008
|
0.91
|
|
24
|
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.
|
Blood
|
2008
|
0.89
|
|
25
|
Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.88
|
|
26
|
Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma
|
2009
|
0.87
|
|
27
|
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.
|
Br J Haematol
|
2011
|
0.87
|
|
28
|
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.87
|
|
29
|
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.
|
Blood
|
2008
|
0.85
|
|
30
|
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia.
|
Clin Lymphoma
|
2005
|
0.84
|
|
31
|
Advances in the biology and treatment of Waldenström's macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden.
|
Clin Lymphoma Myeloma
|
2009
|
0.83
|
|
32
|
Novel agents in the treatment of Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma
|
2007
|
0.83
|
|
33
|
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
|
Leuk Lymphoma
|
2011
|
0.82
|
|
34
|
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma
|
2009
|
0.81
|
|
35
|
Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
|
Blood
|
2011
|
0.81
|
|
36
|
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.81
|
|
37
|
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia.
|
Br J Haematol
|
2009
|
0.81
|
|
38
|
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.79
|
|
39
|
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study.
|
Cancer Epidemiol
|
2011
|
0.79
|
|
40
|
Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.77
|
|
41
|
Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.77
|
|
42
|
Report from the Sixth International Workshop on Waldenström's Macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.77
|
|
43
|
Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.75
|
|
44
|
Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.75
|
|
45
|
Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.75
|